|
|
11100 Bren Rd West
Minnetonka, MN 55343 USA
phone:952-653-1301
fax:952-653-1190
|
|
| Symbol |
Private |
| Founded |
2007 |
| Employees |
9 |
|
|
| www.neochord.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Artificial Chordae Tendineae for Mitral Valve Repair |
|
| Management |
| John Seaberg, CEO; John Zentgraf, VP Research and Development; Annette Doxon, Director Regulatory Affairs and Quality Control; Mary Pekala, Director of Operations; Sharon Iverson, Director of Regulatory Affairs |
| |
|
|
| |
|
| Keywords |
| Cardiology, Cardiac, Mitral Valve Repair, Mitral Regurgitation |
|
|
|
| Description |
|
NeoChord is a specialty medical devices company that has developed a state-of-the art
technology for minimally invasive surgical heart valve repair. The company�s technology
enables the minimally invasive surgical implantation of artificial chordae tendineae while
the heart is still beating. The company's technology eliminates the need for more invasive
approaches, such as sternotomy or cardiopulmonary bypass, thereby addressing the needs
of over 2,000,000 untreated patients in the U.S. |
|
| Products / Services |
NeoChord is commercializing a tool that enables the minimally invasive surgical implantation of artificial chordae tendineae, while the heart is still beating. During normal function, the chordae tendineae tether the mitral valve leaflets to ensure correct closure during ventricular contraction. Rupture of the chordae due to myocardial infarction or degenerative disease is a common cause of mitral leaflet prolapse and subsequent mitral regurgitation.
|
|
| Technology / Differentiation |
| NeoChord's technology eliminates the need for a sternotomy (opening of the chest cavity via sawing of the sternum) and cardio-pulmonary bypass. This less invasive approach can provide less traumatic treatment for surgical patients with fewer complications. It will also allow patients with mitral regurgitation to be treated earlier in the course of their disease, eliminating or slowing the progression of mitral regurgitation into congestive heart failure. |
|
| Market / Customers |
The market for less invasive techniques for mitral valve repair has been estimated at over $2 billion. There are 50,000 surgeries done annually and 250,000 new patients are diagnosed each year with mitral regurgitation in the U.S. alone. Additionally, there are over 2,000,000 U.S. patients with mitral regurgitation who have not been treated because the risks of current procedures are deemed too high compared to the severity of their disease.
|
|
| Funding |
| On July 7th,2009, NeoChord completed a $4.8 ml Series A raise bringing total investment to date to $8.4ml |
|
| Status |
| NeoChord is currently enrolling patients in its European based TACT (transapical artificial chordae tendinae)Trial and expects CE Mark in Europe in mid 2011. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members